AI assistant
Sending…
Vanda Pharmaceuticals Inc. — Director's Dealing 2019
Aug 21, 2019
33390_dirs_2019-08-21_06bf8512-de8a-456e-8310-04f4746949c0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2019-08-19
Reporting Person: Wijkstrom Joakim (SVP, Chief Marketing Officer)
More from Vanda Pharmaceuticals Inc.
Interim / Quarterly Report
2026
May 7
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Regulatory Filings
2026
Apr 22
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Feb 24
Regulatory Filings
2026
Feb 23
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 19